Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...

Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher ...

After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, ...

Teva is planning to reduce its headcount by 8% by 2027, the company announced on Wednesday, as it enters the next phase of ...

FDA advisors to meet May 22 on Covid vaccine strain selection amid scrutiny from Kennedy's HHS, as Novavax awaits approval ...

Gilead is the latest drugmaker to announce that it’s pouring billions of dollars into its manufacturing and R&D operations in ...

Vinay Prasad named to replace Peter Marks as head of FDA's Center for Biologics Evaluation and Research; discussion planned ...

President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing ...

CRISPR Therapeutics has revealed promising but early data from its first clinical study of a gene editing therapy to lower ...

NewAmsterdam's obicetrapib reduced Lp(a) by 45% in Phase 3; C4 Therapeutics advances cemsidomide while dropping CFT1946; Vivo ...

Vertex paused an early-stage trial of its inhaled treatment for cystic fibrosis that came from a partnership with Moderna.